title: The frequency analysis of signal-averaged ECG of P wave as predictor of efficacy of class III antiarrhythmic drugs to maintain sinus rhythm in recurrent idiopathic atrial fibrillation.
abstract: BACKGROUND
  The use of class III antiarrhythmic drugs (ADIII) has been considered a good predictor of sinus rhythm in patients post-cardioversion from atrial fibrillation (AF). Several studies using frequency domain analysis of signal-averaged ECG (FDSAECG) of the P wave were able to identify patients at risk for AF. The aim of this study was to assess the FDSAECG in predicting recurrence of idiopathic persistent AF (IPAF) in patients under ADIII therapy.
  
  
  METHODS
  In 33 patients with two or more previous symptomatic episodes of IPAF, despite classes I and II therapy, the FDSAECG of the P wave was performed during sinus rhythm and free-drug state. The parameters were the mean and standard deviation of the frequency intersegmentar spectral correlation and the standard deviation of the signal frequency edge track. During the follow-up of 30 +/- 18 months, all patients received either amiodarone or sotalol.
  
  
  RESULTS
  During the follow-up, the patients were divided into two groups: Group I-frequent recurrence (>or= three events/year; 16 patients), and Group II-infrequent recurrence (< three events/year; 17 patients). With appropriate cutoff points for each parameter analyzed, intense fragmented electrical activity defined by the presence of at least two abnormal criteria were observed in 13 of 16 patients group I and in 3 of 17 patients group II (P = 0.0003). Sensitivity, specificity, positive and negative predictive values for frequent recurrence were 81.3, 82.4, 81.3, and 82.4, respectively.
  
  
  CONCLUSIONS
  The results suggested that FDSAECG analysis of the P wave accurately predicted patients whose ADIII therapy will be effective in maintaining the sinus rhythm without frequent recurrence of IPAF.
authors.affiliation: Division of Cardiology, State University of Rio de Janeiro, Boulevard 28 de Setembro, 77, Vila Izabel, Rio de Janeiro, Brazil, 20551-030. correabarbosa@uol.com.br
authors.forename: E C
authors.initials: EC
authors.lastname: Barbosa
authors.forename: P R
authors.initials: PR
authors.lastname: Barbosa
authors.forename: P
authors.initials: P
authors.lastname: Ginefra
authors.forename: A
authors.initials: A
authors.lastname: de Souza Bomfim
authors.forename: S H
authors.initials: SH
authors.lastname: Boghossian
authors.forename: P J
authors.initials: PJ
authors.lastname: da Rocha
authors.forename: F M
authors.initials: FM
authors.lastname: Filho
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012680:Sensitivity and Specificity; D012815:Signal Processing, Computer-Assisted; D013015:Sotalol / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D013015:Sotalol; D000638:Amiodarone